For patients and their families during cancer treatment, various resources and temporary housing options aim to ease the ...

Researchers sought to determine whether MSD HSCT or auto-HSCT would have advantages over chemotherapy in post-remission treatment for patients with AML.

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

“AI can enhance clinical decision-making for common acute symptoms in a virtual urgent care setting,” the authors write. “Thoughtful integration of AI into clinical practice, combining its strengths ...

A longitudinal assessment of patient-reported outcomes demonstrated that pexidartinib (Turalio) continues to offer clinically meaningful symptom relief with extended use in patients with tenosynovial ...

Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Incorporating the 40-GEP test with BWH staging and NCCN risk group significantly improved risk stratification.

Physicians should counsel patients considering whether to start treatment for chronic noncancer pain about benefits and harms of cannabis or cannabinoids.

Investigators compared oncologic outcomes among patients with tumors in the bladder only vs in the bladder neck/urethra.

Cadonilimab plus lenvatinib showed promising antitumor activity in patients with advanced endometrial cancer who have experienced disease progression after prior platinum-based chemotherapy,” said ...

CAD may lead to an 8 percent increase in adenoma detection rate and 2 percent increase in detection rate of advanced colorectal neoplasia.

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.